{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-015773","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2025-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.334057+00:00","generated_at":"2026-05-17T05:36:21.468577+00:00","sec_items":["3.02","4.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aspire Biopharma dismisses auditor Bush, appoints Turner Stone; gets $1M funding tranche","bullets":["Dismissed Bush & Associates CPA as independent auditor effective Sept 22, 2025; 2024 audit included going concern explanatory paragraph.","Appointed Turner Stone & Co. as new independent auditor for FY 2025, effective Sept 22, 2025.","No disagreements with Bush; material weaknesses in internal control over financial reporting were disclosed.","Received $1M second tranche funding under Securities Purchase Agreement for notes with aggregate principal $9.6875M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-015773","json":"https://secwatch.observer/filing/0001493152-25-015773.json","markdown":"https://secwatch.observer/filing/0001493152-25-015773.md","text":"https://secwatch.observer/filing/0001493152-25-015773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315225015773/0001493152-25-015773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315225015773/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:36:21.468577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ebbd82123903fdc57885855519b09f8db889d99","claim":"Aspire Biopharma Holdings, Inc. dismissed Bush & Associates CPA as its auditor.","evidence_excerpt":".01 Changes in Registrant’s Certifying Accountant (a) Termination of Previous Independent Registered Accounting Firm On September 22, 2025 Bush & Associates CPA ( “Bush” ) was dismissed by the Audit Committee of the Board of Directors of Aspire Biopharma Holdings, Inc.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315225015773/0001493152-25-015773-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Bush & Associates CPA"},{"label":"Successor","value":"Turner Stone & Co"}],"fact_type":"auditor_change"},{"claim_id":"631a2892b2a5e260b6e197580f3d02e84ec6b792","claim":"Aspire Biopharma Holdings, Inc. engaged Turner Stone & Co as its auditor.","evidence_excerpt":"(b) Appointment of New Independent Registered Public Accounting Firm On September 22, 2025, the Company’s Audit Committee approved the engagement of Turner Stone & Co ( “Turner” ) as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847345/000149315225015773/0001493152-25-015773-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Turner Stone & Co"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}